Summary & Overview
HCPCS J9021: Injection, Asparaginase (Rylaze), 0.1 mg
HCPCS Level II code J9021 represents the injection of recombinant asparaginase (Rylaze), billed per 0.1 mg unit. This oncology drug code is used to capture administration and drug acquisition costs for a specialized chemotherapeutic agent indicated in certain leukemias. Nationally, accurate coding for high-cost oncology injectables affects payment integrity, utilization management, and patient access to therapy.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find clinical and billing context for J9021, including typical service settings (outpatient infusion centers and hospital outpatient departments), what the code denotes clinically, and the analytic scope of coverage and benchmarking where available. The report outlines common payer considerations, such as prior authorization and site-of-care implications, and highlights the importance of precise unit reporting for per-milligram drugs.
This summary provides a national perspective on service coding, payer coverage patterns, and the operational implications for providers and billing teams. Data not available in the input are noted where applicable, and the content focuses on descriptive and policy-relevant information rather than clinical recommendations.
Billing Code Overview
HCPCS Level II code J9021 denotes an injection of recombinant asparaginase (Rylaze), dosed per 0.1 mg. This code represents a single unit measure for administration of the medication used in oncology care, specifically for asparaginase therapy.
Service Type: Therapeutic injection / oncology drug administration
Typical Site of Service: Outpatient infusion center or hospital outpatient department
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A pediatric or young adult patient with acute lymphoblastic leukemia (ALL) receiving systemic chemotherapy in an outpatient infusion center or inpatient oncology ward. The patient is scheduled to receive recombinant asparaginase (J9021, 0.1 mg units) as part of an induction or consolidation chemotherapy regimen. Typical workflow: review of oncology orders and recent labs (including hepatic panel, coagulation studies, and serum asparagine if available), assessment for prior hypersensitivity to asparaginase products, verification of venous access (peripheral IV or central line), preparation of the reconstituted product by pharmacy, administration by an oncology nurse with appropriate monitoring for hypersensitivity reactions and pancreatitis, documentation of lot number and expiration, and billing using J9021 with any applicable modifier (for example JW for discarded drug or QK/QX for pharmacist/qualified person services). Typical site of service: outpatient hospital infusion center, physician office oncology clinic, or inpatient hospital floor depending on clinical status. Typical patient scenario: a 10-year-old child on day 8 of induction presenting to the pediatric oncology infusion unit for scheduled asparaginase dosing; baseline labs reviewed and within acceptable ranges, no prior anaphylaxis, dose prepared by pharmacy and administered via peripheral IV with 60 minutes of observation post-infusion for immediate reactions.
Coding Specifications
| Modifier | Description |
|---|